"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

GSK’s blood cancer drug Blenrep has been reapproved by the EU medicines regulator after it was removed from sale in 2023 because a trial failed to show it was superior to other treatments.

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

Prefilled syringe eliminates the need to reconstitute separate vials prior to administration and simplifies the vaccine process.

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

And other biotech news brought to you by The Readout.

The US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for ...